In a randomized, double-blind, placebo-controlled crossover trial of 30 adults with obesity (Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Blundell and colleagues, Diabetes, Obesity and Metabolism , 2017), 12 weeks of once-weekly semaglutide titrated to 1.0 mg was associated with less hunger, fewer food cravings, better control of eating, and a lower preference for high-fat foods
This pattern reflects the medication's role in appetite control rather than a permanent metabolic reset
What changes at 0.50mg: Appetite suppression typically becomes more pronounced Food thoughts diminish (less "food noise") Portion sizes naturally decrease Early weight loss may begin (1 to 2 pounds per week is common) GI side effects may temporarily increase before settling Some compounded semaglutide protocols allow for a half-step at 0.375mg if the jump from 0.25mg to 0.50mg causes intolerable side effects
Can You Switch From Semaglutide to Tirzepatide
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A Retrospective Observational Pharmacy Claims Analysis
